European Commission authorises second safe and effective vaccine against COVID-19

(Credit: Unsplash)

This article is brought to you in association with the European Commission.


Today, the European Commission has granted a conditional marketing authorisation (CMA) for the COVID‑19 vaccine developed by Moderna, the second COVID-19 vaccine authorised in the EU. This authorisation follows a positive scientific recommendation based on a thorough assessment of the safety, effectiveness and quality of the vaccine by the European Medicines Agency (EMA) and is endorsed by the Member States.

The President of the European Commission, Ursula von der Leyen, said: “We are providing more COVID-19 vaccines for Europeans. With the Moderna vaccine, the second one now authorised in the EU, we will have a further 160 million doses. And more vaccines will come. Europe has secured up to two billion doses of potential COVID-19 vaccines. We’ll have more than enough safe and effective vaccines for protecting all Europeans.”

Stella Kyriakides, Commissioner for Health and Food Safety, said: “We are all in this together and united. This is why we have negotiated the broadest vaccine portfolio in the world for all our Member States. Today we are authorising a second safe and effective vaccine from Moderna, which together with BioNTech-Pfizer, will ensure that 460 million doses will be rolled out with increasing speed in the EU, and more will come. Member States have to ensure that the pace of vaccinations follows suit. Our efforts will not stop until vaccines are available for everyone in the EU.”

Moderna submitted on 30 November 2020 an application for marketing authorisation to EMA, which had already started a rolling review of the data in November. Thanks to this rolling review, EMA has been assessing the quality, safety and efficacy of the vaccine as data has become available. EMA’s human medicines committee (CHMP) has thoroughly assessed the data and recommended by consensus that a formal conditional marketing authorisation is granted. A conditional marketing authorisation is one of EU’s regulatory mechanisms for facilitating early access to medicines that fulfil an unmet medical need, including in emergency situations such as the current pandemic.

On the basis of EMA’s positive opinion, the Commission has verified all the elements supporting the marketing authorisation and consulted Member States before granting the conditional market authorisation.

The Moderna vaccine is based on messenger RNA (mRNA). mRNA plays a fundamental role in biology, transferring instructions from DNA to the cells’ protein making machinery. In an mRNA vaccine, these instructions produce harmless fragments of the virus, which the human body uses to build an immune response to prevent or fight disease. When a person is given the vaccine, their cells will read the genetic instructions and produce a spike protein, a protein on the outer surface of the virus which it uses to enter the body’s cells and cause disease. The person’s immune system will then treat this protein as foreign and produce natural defences — antibodies and T cells — against it.

Next steps

Moderna, with whom the Commission signed a contract on 25 November, will deliver the total amount of 160 million doses between the first and the third quarters of 2021. It will add to the 300 million doses of the vaccine distributed by BioNTech/Pfizer, the first vaccine to have been authorised in the EU on 21 December 2020.

Background

A conditional marketing authorisation (CMA) is an authorisation of medicines on the basis of less complete data required for a normal marketing authorisation. Such a CMA may be considered if the benefit of a medicine’s immediate availability to patients clearly outweighs the risk linked to the fact that not all the data are yet available. However, once a CMA has been granted, companies must provide within certain deadlines further data including from ongoing or new studies to confirm that the benefits continue to outweigh the risks.

Moderna submitted on 30 November 2020 an application for a CMA for their vaccine to EMA. EMA has already been assessing data on the vaccine’s safety, effectiveness and quality and results from laboratory studies and clinical trials in the context of a rolling review. This rolling review and the assessment of the CMA application allowed EMA to quickly conclude on the safety, effectiveness and quality of the vaccine. EMA recommended granting the conditional marketing authorisation as the benefits of the vaccine outweigh its risks.

The European Commission has verified whether all necessary elements – scientific justifications, product information, educational material to healthcare professionals, labelling, obligations to marketing authorisation holders, conditions for use, etc. – were clear and sound. The Commission also consulted the Member States, as they are responsible for the vaccines marketing and the use of the product in their countries. Following the Member States’ endorsement and on the basis of its own analysis, the Commission decided to grant the conditional market authorisation.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

Can India reduce deaths on one hazardous road to zero? This group is trying

COVID-19 tracing apps: MEPs stress the need to preserve citizens’ privacy

Politics still matter in the US but not in Europe

MEPs list conditions for new EU-Azerbaijan deal

South Korea once recycled 2% of its food waste. Now it recycles 95%

The unique role of business in building social good

Will the French let Macron destroy their party political system?

Yemen: ‘Living hell’ for all children, says UNICEF; Angelia Jolie calls for ‘lasting ceasefire’

Brexit: UK business fear of a no-deal scenario preparing for the worst

How to build long-term resilience in vulnerable communities

EU-UK relations: solutions found to help implementation of the Protocol on Ireland and Northern Ireland

This woman changed the world of work – and you’ve probably never heard of her

The Eurogroup offered a cold reception to IMF’s director for Europe

Trump stumbles badly on his Russian openings; Europeans wary of Putin

COVID-19: EU helps to deliver vaccines to Moldova and medical items to Montenegro and North Macedonia

Boosting the EU’s Green Recovery: EU invests over €2 billion in 140 key transport projects to jump-start the economy

4 ways to improve the lives of older people

Antitrust: Commission imposes binding obligations on Gazprom to enable free flow of gas at competitive prices in Central and Eastern European gas markets

EU4Health: 9.4 billion EUR budget needed for new EU health programme

A Sting Exclusive: “One year on from the VW scandal and EU consumers are still in the dark”, BEUC’s Head highlights from Brussels

European Semester 2018 Spring Package: Commission issues recommendations for Member States to achieve sustainable, inclusive and long-term growth

The French army is enlisting sci-fi writers to predict the future

What meat consumption has brought to the environment and how herbal diets can help human health

Here’s the secret to financing a greener future

Anti-vaccination: a private choice leading to collective outcomes

Consumer product quality: MEPs take aim at dual standards

This is how we can save millions of people from extreme poverty after COVID-19

Yemen: Security Council backs new mission in support of key port city truce

Scientists have created the world’s ‘first psychopath AI’

UN refugee agency presses States to aid 49 refugees stranded on Mediterranean

Take medical use of cannabis seriously, say MEPs

First-ever EU defence industry fund to finance joint development of capabilities

Parliament toughens its position on banking union

West Darfur tensions could see 30,000 flee across Sudanese border to Chad: UN refugee agency

China dazzles the world with her Silk Road plan to connect, Asia, Europe and Africa

Budgetary Control Committee asks for stronger measures to protect EU spending

Europe plans to send satellites into space to monitor CO2 emissions

Euro-Mediterranean Assembly fixes its permanent seat in Rome

EU to lead one more fight against climate change at G7 summit

New EU visa rules – Questions and Answers

4 ways leaders are driving innovation in the public sector and revolutionising governance

Electronic Cigarettes: A booster or alternative to Smoking?

Fostering intergenerational solidarity and cooperation through age-friendly environments: the right answer to Europe’s demographic challenge

‘Virtual Biopsy’ device detects skin tumours in 15 minutes

Where EU air pollution is deadliest

Eurogroup: IMF proposes Germany disposes

Where do Americans stand on immigration? They’re not as divided as you might think

“Scalpel, please”. For how long hearing this from a woman will be a surprise?

These are the skills young people will need for the green jobs of the future

Mergers: Commission clears acquisition of joint control over INWIT by Telecom Italia and Vodafone, subject to conditions

Why infrastructure is the only way to fight a COVID-19 recession in the US

MEPs want ambitious funding for cross-border projects to connect people

A Europe that Protects: Commission calls for more efforts to ensure adoption of security proposals

Nigeria floods: Guterres ‘deeply saddened’ by loss of life and rising need

EU young translators’ contest kicks off!

How trade wars pose a threat to the global economy

Why precision medicine won’t transform healthcare – but governance could

Fairer, simpler, more flexible EU farm policy: MEPs vote on post-2020 reform

#WorldBicycleDay: 5 benefits of cycling

Investing in rural women and girls, ‘essential’ for everyone’s future: UN chief

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: